Navigation Links
Oncology Physician Resource (OPR) Extends Agreement With OTN and Onmark as Oncology Services Partner
Date:11/5/2007

SOUTH SAN FRANCISCO, Calif., Nov. 5 /PRNewswire/ -- OTN, a leading physician services company and one of the largest distributors of products and services to the community physician market, and Onmark, a national group purchasing organization (GPO) for community-based practices, today announced that Oncology Physician Resource (OPR) has extended its existing partnership with OTN and Onmark for another year. Under the extended agreement, which is worth more than $200 million, OTN and Onmark will continue to provide OPR members with a wealth of oncology services, including drug distribution resources, technology and practice management solutions, clinical services, educational opportunities and GPO services.

OPR is a professional limited liability company owned by physician members who are dedicated to strengthening oncology practices through optimizing operational efficiencies and maximizing purchasing power. OPR represents approximately 100 oncologists in 42 practices at 77 sites located primarily in Michigan.

"We are continuing our successful partnership with OTN and Onmark because we are very pleased with their outstanding customer service, competitive pricing and commitment to innovation. We look forward to extending our relationship to continue to provide value to our OPR members," said Philip Stella, M.D., President and CEO of OPR.

OTN provides the broadest set of services, technology, pharmaceuticals, supportive care products and medical/surgical supplies to physicians practicing in the community-treatment setting. Under the extended agreement, OPR's members will continue to have access to OTN's Lynx(R) oncology-specific, web-based technology platform, which includes Lynx Mobile(TM), Lynx EMR(TM), Lynx Station,(TM) Lynx Practice Manager(TM); and other practice management tools, including Lynx Practice Intelligence(TM) Reports.

Through Onmark, OPR members will continue to have access to competitive contracts for oncology drugs fro
'/>"/>

SOURCE OTN
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...le the U.S. AIDS epidemic simmers largely unnotice... routine HIV testing continues to fuel its spread,...,000 Americans were infected with HIV last year, a...ransmitted infections are spread by people who do ...wo years ago by the U.S. Centers for Disease Contr...
(Date:11/20/2008)... respiratory disease , , THURSDAY, Nov. ...uring ovulation may explain why women with cystic ...iratory disease, researchers at the University of ...udy, published in the Nov. 20 issue of the Journa...hat reduce estrogen levels, such as tamoxifen, mig...
(Date:11/20/2008)...am of researchers at Duke University Medical Cente...s found that lactic acid is an important energy so... discovered a new way to destroy the most hard-to-...m delivering lactic acid. , "We have known for...ells cause resistance to radiation therapy," said ...
(Date:11/20/2008)...on Therapeutics Inc., a leader,in the development...3 million,in additional funding to expand the dev...emoFx is a diagnostic test that helps physicians s... for cancer patients. New investor,Longitude Ve... by existing,investors Adams Capital Management, ...
Breaking Medicine News(10 mins):Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 2Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 3Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 4Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 5Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:Lactic acid found to fuel tumors 2Health News:Precision Therapeutics Secures $43 Million in Venture Capital Funding 2Health News:Precision Therapeutics Secures $43 Million in Venture Capital Funding 3
...n against bird flu has been studied and the findin...ity of Rochester. // This involves a way of gettin...lu hits, it would take months to develop a vaccine...required to prevent infection. The idea behind th...
...ative combination of 3 HIV/AIDS drugs, Viraday tha...treatment. // The three anti-HIV drugs efavirenz ...omprise the drug Viraday.Viraday, one tablet of wh...ected person, eliminates the need for 3 separate m...
...lly used to treat ulcers, was found to prevent exc...h of women in developing countries, according// to...onal, the University of Missouri, India's Jawaharl...onal Institutes of Health. The study, published i...
...ceston General Hospital have developed a revolutio...irector of the LGH Dementia Research Centre George... can treat one type of dementia. Over 5000 Tasmani...ementia and the figure is predicted to rise three-...
Other Medicine News:Health News:Ulcer Drug Could Save Lives of Women in Developing Countries 2
(Date:11/20/2008)...RNewswire/ -- Milk. It does a body good. And,now ... After years of,research, scientists at OncoNutri...milk that stimulate the body,s own production of a...ews Release, go to:, http://www.prnewswire.com/mnr... new cancer therapies, the chief scientist, Dr. Da...
(Date:11/20/2008).../ -- Clinical data from a prospective,registry pr...um shows DVT,treatment with the Trellis(R) Periph...(Santa Clara, CA) successfully breaks up the blood... This technique, called isolated pharmacomechan...ly and safely than current catheter-directed throm...
(Date:11/19/2008)...9 Amgen,(Nasdaq: AMGN...subsidiary of,Takeda Pharmaceutical Company Limit...n the Phase 3 MONET1 trial evaluating motesanib (A...latin for the first-line treatment of,advanced no...ily suspended,following a planned safety data rev...
(Date:11/19/2008)...wire/ -- Isogen, a contract development and,manuf...nnounced the first,phase launch of its contract f...ically address the process, facility and capacity ...highly-niched, low-volume clinical and,early-stag... Companies can invest over $100 million and fou...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2Blood clotting protein modified for people with hard to treat hemophilia 19781 1Blood clotting protein modified for people with hard to treat hemophilia 19781 2Abnormal editing of gene messages may be a cause of lupus 19779 1Abnormal editing of gene messages may be a cause of lupus 19779 2Wells Fargo Health Savings Accounts Grow to Quarter Billion Dollars 19777 1Wells Fargo Health Savings Accounts Grow to Quarter Billion Dollars 19777 2Pivotal Study Shows Physician Nurse Teams Using SEDASYS 28TM 29 System Reduced Risk of Over Sedation With Propofol 2121 1Pivotal Study Shows Physician Nurse Teams Using SEDASYS 28TM 29 System Reduced Risk of Over Sedation With Propofol 2121 2Pivotal Study Shows Physician Nurse Teams Using SEDASYS 28TM 29 System Reduced Risk of Over Sedation With Propofol 2121 3Pivotal Study Shows Physician Nurse Teams Using SEDASYS 28TM 29 System Reduced Risk of Over Sedation With Propofol 2121 4
...ces Deal for Vaccine Delivery System, NYON, Switze...metics Corporation announced today that the Compan... a non-human primate model.,Mucosal IgA antibodies...gainst infection by HIV. The data were presented b...c Officer in an,oral presentation, "Without Mucosa...
...rch 29, 2007 /PRNewswire-FirstCall/ -- Baxter,Inte...ta for its,adjuvant-free investigational pandemic ...se III clinical trial of the candidate,vaccine in .../II study indicated that Baxter,s H5N1 candidate,v...uces substantial,levels of cross immunity against ...
Other Medicine Technology:Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5
AccuSign® DOA Series Opiates Test
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP).
Unlike other ESR products, SEDIPLAST® is a completely closed system with superior design features to protect laboratory personnel from the risk associated with blood handling. SEDIPLAST® is a
Unlike other ESR products, SEDIPLAST® is a completely closed system with superior design features to protect laboratory personnel from the risk associated with blood handling. SEDIPLAST® is a
Medicine Products: